

# ASTELLAS PHARMA INC.

ISIN: JP3942400007 WKN: 4503 Asset Class: Stock

## Company

2024/04/23 08:00:00



**Price**  
**1,491.50**  
JPY

**Difference** ▲  
1.05%(15.50)



## Contact Details

ASTELLAS PHARMA INC. Tel: +81-3-3244-3000  
 -- Fax: +  
 2-5-1 Nihonbashi-Honcho, Chuo-Ku Web: <http://www.astellas.com>  
 103-8411 Tokyo E-mail: -

## Company Profile

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

## Financial figures, Fiscal year: from 01.04. to 31.03.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	1,049,954,000,000		923,354,000,000		872,588,000,000	
<b>Common stock capital</b>		103,001,000,000		103,001,000,000		103,001,000,000
<b>Fixed assets</b>	1,406,564,000,000		1,409,041,000,000		1,401,040,000,000	
<b>Equity capital of a company</b>		1,507,954,000,000		1,460,308,000,000		1,386,115,000,000
<b>Cash and cash equivalents</b>	376,840,000,000		315,986,000,000		326,128,000,000	
<b>Accrued liabilities</b>		67,859,000,000		77,207,000,000		74,048,000,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		726,034,000,000		687,411,000,000		592,372,000,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		222,530,000,000		184,675,000,000		295,142,000,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		37,162,000,000		46,631,000,000		60,770,000,000
<b>Total assets</b>	2,456,518,000,000	2,456,518,000,000	2,332,395,000,000	2,332,395,000,000	2,273,628,000,000	2,273,628,000,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	14,484	14,522	15,455
<b>Equity ratio</b>	61.39%	62.61%	60.96%
<b>Debt-equity ratio</b>	62.90%	59.72%	64.03%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	25.66%	20.97%	17.08%

# ASTELLAS PHARMA INC.

ISIN: JP3942400007 WKN: 4503 Asset Class: Stock

## Income statement

	2023	2022	2021
<b>Turnover</b>	1,518,619,000,000	1,296,163,000,000	1,249,528,000,000
<b>Net income</b>	98,714,000,000	124,086,000,000	120,589,000,000
<b>EBIT</b>	790,023,200	979,367,200	893,637,800
<b>Operating income before taxes</b>	131,101,000,000	156,397,000,000	144,846,000,000
<b>Cash Flow</b>	332,325,000,000	258,160,000,000	307,880,000,000
<b>Net interest income</b>	1,589,000,000	-4,155,000,000	-1,652,000,000
<b>Research and development expenses</b>	276,128,000,000	246,010,000,000	224,489,000,000
<b>Income taxes</b>	33,647,000,000	32,800,000,000	24,734,000,000
<b>Result from investments in subsidiaries, associates and other</b>	1,260,000,000	489,000,000	478,000,000
<b>Revenues per employee</b>	639,573	544,456	493,182

## Board of Directors

Kenji Yasukawa	Chairman of Supervisory Board
Eriko Sakurai	Member of Supervisory Board
Haruko Shibumura	Member of Supervisory Board
Hiroko Sakai	Member of Supervisory Board
Hiroo Sasaki	Member of Supervisory Board
Hiroshi Kawabe	Member of Supervisory Board
Katsuyoshi Sugita	Member of Supervisory Board
Mamoru Sekiyama	Member of Supervisory Board
Mika Nakayama	Member of Supervisory Board
Noriyuki Uematsu	Member of Supervisory Board
Takashi Tanaka	Member of Supervisory Board
Tatsuro Ishizuka	Member of Supervisory Board
Tomokazu Fujisawa	Member of Supervisory Board

## Members of Management Board

Kenji Yasukawa	Chairman of Managing Board
Bernie Zeiher	Member of Executive Committee
Catherine Levitt	Member of Executive Committee
Fumiaki Sakurai	Member of Executive Committee
Hideki Shima	Member of Executive Committee
Minoru Kikuoka	Member of Executive Committee
Naoki Okamura	Member of Executive Committee
Yoshihitsu Shitaka	Member of Executive Committee
Yukio Matsui	Member of Executive Committee